It’s time to put the power of PharmOptima to work on your preclinical and early stage clinical programs.

Since 2003, PharmOptima has been advancing drug discovery and development in various therapeutic areas and has filled a niche in ocular drug development.

PharmOptima’s in vivo services include studies in the fields of drug absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK), and pharmacology. We provide liquid chromatography and mass spectrometry (LC-MS/MS) bioanalysis in support of discovery and development programs, including method development and validation in accordance with regulatory guidelines.

Our biochemistry expertise allows us to assess the role of biomarkers in numerous disease models.The biochemical capabilities include in vitro and cell based assay development for compound profiling as well as protein cloning and expression.

Our expertise extends to the custom development of enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence multiplex formats.

PharmOptima is a member of Genesis Drug Discovery and Development (GD3) the contract research organization (CRO) of Genesis Biotechnology Group® (GBG). GD3 is a preclinical Contract Research Organization which offers an integrated portfolio of drug discovery services from target validation and assay development to advancing compounds from “hit to lead” to “lead optimization”. GD3’s three portfolio companies. Additional members include:

  • Venenum Biodesign

    Venenum Biodesigns is composed of biologists and chemists with years of experience identifying validated small molecule drug targets across therapeutic areas. Once validated, we develop state-of-the-art assays and models for HTS or Rational design.

  • Invivotek

    Invivotek is focused on custom and standard in vivo drug testing services and phenotypic characterization of genetically modified rodents to support drug discovery and development programs of clients.

  • NexusPharma

    NexusPharma is dedicated to the discovery of innovative anti-cancer treatments. Novel drug candidates are tested in patient derived xenograft tumor models or patient derived tumor cell lines that are derived from such PDX models.